| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.10B | 919.69M | 776.05M | 569.14M | 302.32M | 50.24M |
| Gross Profit | 429.62M | 363.01M | 372.27M | 303.29M | 153.69M | 21.22M |
| EBITDA | -19.20M | 122.52M | 101.88M | 95.99M | 21.27M | -495.00K |
| Net Income | -128.62M | 32.61M | 82.00K | 19.07M | -30.69M | -2.62M |
Balance Sheet | ||||||
| Total Assets | 2.02B | 1.81B | 1.41B | 1.32B | 1.26B | 262.73M |
| Cash, Cash Equivalents and Short-Term Investments | 98.89M | 131.67M | 43.42M | 48.91M | 61.92M | 86.89M |
| Total Debt | 569.76M | 425.09M | 426.28M | 358.42M | 401.94M | 23.57M |
| Total Liabilities | 1.03B | 877.55M | 563.16M | 503.78M | 554.37M | 43.75M |
| Stockholders Equity | 826.20M | 867.61M | 767.67M | 732.34M | 618.24M | 217.37M |
Cash Flow | ||||||
| Free Cash Flow | -17.33M | -6.70M | 37.20M | 70.14M | 19.59M | -6.52M |
| Operating Cash Flow | 3.93M | 9.52M | 66.44M | 76.55M | 22.27M | -5.38M |
| Investing Cash Flow | -86.18M | -60.23M | -106.42M | -37.93M | -499.78M | -44.21M |
| Financing Cash Flow | 133.09M | 133.50M | 10.63M | -52.85M | 452.53M | 120.84M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | C$2.17B | -46.32 | -2.58% | 0.69% | 9.94% | 35.48% | |
63 Neutral | C$259.74M | 2.03 | 41.13% | 2.47% | -35.35% | 948.72% | |
56 Neutral | C$229.69M | 3,650.00 | 0.11% | 0.54% | 0.19% | ― | |
55 Neutral | C$26.19M | 157.89 | 0.69% | ― | 11.89% | 5.56% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | C$1.26B | -9.60 | -14.61% | ― | 20.36% | -186.10% |
WELL Health Technologies Corp reported record financial results for Q3-2025, with revenues reaching $364.6 million, a 56% increase from the previous year, driven by organic growth and acquisitions. The company achieved a record Adjusted EBITDA of $59.9 million, marking a 296% increase, and highlighted improvements in operational efficiency and patient visits in its Canadian clinics. WELLSTAR, a majority-owned subsidiary, secured $62 million in financing, reflecting strong market confidence and positioning it for future growth and an IPO.
The most recent analyst rating on (TSE:WELL) stock is a Hold with a C$6.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.
WELL Health Technologies Corp’s subsidiary, WELLSTAR Technologies, has announced a C$62 million equity placement to support its growth strategy ahead of a planned spinout. The financing, backed by prominent Canadian investors, is expected to close in December 2025 and will be used for AI innovation, acquisitions, and organic growth. This move highlights investor confidence in WELLSTAR’s performance and positions the company for a public listing in 2026, offering direct investment opportunities in a high-growth healthcare technology firm.
The most recent analyst rating on (TSE:WELL) stock is a Hold with a C$5.25 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.
WELL Health Technologies Corp. announced it will release its Fiscal Third Quarter 2025 financial results on November 6, 2025. The company will hold a conference call and webcast on the same day to discuss the results, which could provide insights into its operational performance and market positioning.
The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$9.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.
WELL Health Technologies Corp reported record financial results for Q2-2025, achieving a 57% increase in quarterly revenues to $356.7 million, driven by organic growth and acquisitions. The company also marked its first-ever quarter with over 1 million patient visits in Canada, reflecting a 38% year-over-year growth. WELL’s strategic investments in Canadian clinics and technology have led to improved provider productivity and significant milestones in financial metrics, including Adjusted EBITDA and net income. The inclusion of HEALWELL AI contributed $40.5 million to revenue, and the company is considering strategic alternatives for its U.S. assets to focus on core Canadian operations.
The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.